Poster area

All posters will be presented in the foyer of the Quays Theatre (1st floor). The number of the abstract is displayed in the abstract pdf on the website and on the poster board.

Posters on display
  • The poster area is open for poster viewing on Tuesday, July 10 and Wednesday, July 11
  • On Tuesday, poster presenters are requested to be present at their poster in order to answer questions from delegates, between 17:00 – 18:00 hours.
Poster mounting
  • Posters should be mounted on Tuesday July 10 by 12:00 hours.
  • The number of the posters can be found in the Abstract pdf on the website.
  • Posters should be mounted with blue tag provided by the organisation.
  • Posters should be mounted with a blue tag (provided by the IHS/seminar organization) only.
  • Setting-up a poster generally takes at least 10 minutes.
Poster material removal
  • Material should be removed between 15.00 and 16.00 hours on Wednesday, July 11
  • Material that has not been taken down by the author(s) will be removed and disposed of by the Organizers.




P-01       Evaluating the understanding and awareness of staff nurses concerning safe transfusion
Ali M., Harani M., (Pakistan)

P-02       Inactivation of high levels of plasmodium falciparum in all blood components by nucleic acid targeting treatment
Payrat J.M., Laughhunn A., Sow C., Grellier P., Lobo C., Lanteri., Bringmann P. (USA)

P-03       Communication failures contribute to transfusion delays in emergencies: evidence from Serious Hazards of Transfusion (SHOT) haemovigilance scheme
Carter-Graham S. M. (United Kingdom)

P-04       Safety and Efficacy of Amotosalen-UVA inactivated plasma to treat thrombocytic thrombocytopenic purpura with therapeutic plasma exchange
Garraud O,. Coppo P., Malot S., Lin J. S. (France)

P-05       Untargeted “label free” proteomics study to understand platelet transfusion adverse reaction
Garraud O., Laradi S., Cognasse F., Guyotat D., Tavernier E., Fagan E., Claverol S., Aloui C., Barlier C., (France)

P-06       Performance indicators: A tool for continuous quality improvement at Nakasero National Blood Bank
Gerald N. (Uganda)

P-07       Pulmonary complications of transfusion -Transfusion Related Acute Lung Injury : A case report
Jain A K., Jain R., Choudhury N. (India)

P-08       Platelet proteome changes during platelet transfusion adverse reaction
Laradi S., Garraud O., Hamzeh-Cognasse H., Tavernier E., Claverol S., Fagan J., Aloui C., Barlier C. (France)

P-09       Acute Transfusion Reactions in a Teaching Hospital in Ghana
Owusu-Ofori A., Owusu-Ofori S., Nsiah S., Wilkinson S., Masaki M., Cardoso Marcia., Knox P. (Ghana)

P-10       Rare adverse reactions in the transfusion recipient:  A case report of TA-GvHD
Politis C., Asariotou M., Richardson C., Grouzi E., Cheropoulou A., Panagou I., Giannouli S., Nomikoy E. (Greece)

P-11       Surveillance of transfusion-transmitted infections in accepted blood donors in Greece: The issue of co-infections
Politis C., Kavallierou L., Zervou E., Hatzitaki M., Martinis G., Asariotou M., Richardson C. (Greece)

P-12       Research on transfusion reactions in 33 hospitals of Sichuan province
Kong Y., Tian X., He R., Liu Z. (China)

P-13       A Retrospective Grade Assessment Study on Reported Transfusion Reactions in China
Tian X., Kong Y., Liu Z. (China)

P-14       Transfusion management of trauma  patients in resuscitation unit
Vasiljevic-Jovanovic B., Milenkovic M., Zivotic B., Mladenovic N., Dinic R., Bogdanovic G. (Serbia)


 P-15       The pattern of transfusion transmitted infections (TTIs) screening test results among blood donors in ratnapura regional blood centre (RRBC), Sri Lanka (SL)
de Alwis I., Manjula N., Thilini N. (Sri Lanka)

P-16       Adverse Events in Platelet Apheresis Donation and their Impact on Donor Retention.
Freeney P. (Ireland)

P-17       Haemovigilance Blood Donors. Experience  Matanzas  Province, Cuba
Silva Ballester H. M., Lopez R. (Cuba)


 P-18       Radio Frequency Identification Technology (RFID) – An emerging technology in Transfusion Medicine
Ajeneye F. (United Kingdom)

P-19       Residual risks of Transfusion-Transmitted Viral Infections
Goto N., Oda A., Miwa I., Taira R., Satake M. (Japan)

P-20       Evaluation of a new approach of expertise of the ARs: Application to TRALI
Sandid I., Boudjedir K., Gautier A., Drougard S., Sainte-Marie I., Boudali L. (France)

P-21       Traceability of blood transfusions and reporting of adverse reactions in developing countries: a six-year post-pilot phase experience in Burkina Faso
Sawadogo S., Nebie K., Milogo T., Kafando E., Deneys V. (Burkina Faso)

P-22       Results of the territorial active Haemovigilance program in Matanzas province, Cuba. 2015 to 2017
Silva Ballester H. M. (Cuba)

P-23       Developing Methods for Active Hemovigilance on a Broad Scale: The US FDA Biologics Effectiveness and Safety (BEST) Initiative
Whitaker B., Wlliams A., Shoaibi A., Reich C., Dempster S., Anderson S. (USA)


17 - 19 March
Workplace Oo - Oslo, Norway

Registration postponed